Navigation Links
Pierre Fabre Dermatologie Starts Clinical Trials on a Beta-Blocker to Treat Severe Infantile Haemangioma
Date:5/6/2009

CASTRES, France, May 6 /PRNewswire/ -- Pierre Fabre Dermatologie, specialised department of Pierre Fabre Laboratories, is proud to announce the launch of a set of clinical trials following the signature of an exclusive and worldwide licence agreement on July 10th 2008 with the University of Bordeaux. The contract covers the development, production and marketing of a paediatric beta-blocker for the treatment of severe infantile haemangioma with the intention of obtaining NDA-approval (New Drug Application) both for Europe and the USA. Patents were also applied for in this indication.

The efficacy of beta-blockers on haemangioma was discovered by Dr. Christine Leaute- Labreze, dermatologist in Pr. Alain Taieb's department in Bordeaux. "Effectiveness of this treatment has been demonstrated in several hundred children throughout the world. Rigorous clinical trials are, however, yet to be conducted to ascertain the efficacy and tolerance of this new therapeutic strategy, hence this agreement with Pierre Fabre Dermatologie, which would ensure safety and availability of the treatment."

This therapeutic breakthrough has been widely talked about, not only during scientific conferences but also through professional and general-interest press.

"This is a major discovery that will bring true therapeutic advance to patients affected by this highly apparent disease, which can be very severe and can have a strong impact on their quality of life and that of their parents. For this reason, we are highly honoured to have signed this agreement with the University of Bordeaux on severe haemangioma," specifies Jacques Fabre, General Manager of Pierre Fabre Dermocosmetique.

About haemangioma:

Infantile haemangioma refers to a vascular tumour highly prevalent in infants, with a 10% concurrency rate. Haemangioma occurs in the first months of life and is located on the face in 60% of cases
'/>"/>

SOURCE Pierre Fabre SA
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Bristol-Myers Squibb and Pierre Fabre Provide Update On Vinflunine Development Status
2. Carrington Subsidiary DelSite Starts Making Test Batches of First Bird Flu Vaccine Offering Needle-free Self-Administration
3. Evotec Starts Phase II in Smoking Cessation with EVT 302
4. Synosia Starts Phase II Efficacy Trial For Rufinamide
5. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Combination REOLYSIN(R)/Cyclophosphamide Trial
6. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
7. Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws in Children
8. AMT Starts Collaboration With St. Jude Childrens Research Hospital on Gene Therapy for Hemophilia B. Company Accesses Exclusive Commercial Rights to Final Therapy
9. Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics
10. Gerresheimer Starts Process to Sell off its Business Segment of Technical Plastics
11. Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... PORTLAND, Oregon , July 29, 2014 ... titled, "Global surgical equipment market (types, applications and geography) ... Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - ... expected to reach $12.1 billion by 2020 registering a ... Due to the breakthrough achieved by the electro surgical ...
(Date:7/29/2014)... Philadelphia’s newest entrepreneurial incubation space is ready for ... The Innovation Center @3401 , a collaborative effort of ... to help attract and nurture start-up businesses in the ... , The Innovation Center @3401 (ic@3401), which is ... the new home of DreamIt Ventures and ...
(Date:7/29/2014)... 2014  United Therapeutics Corporation (NASDAQ: ... results for the second quarter ended June 30, ... that our medicines are reaching increasing numbers ... (PAH)," said Martine Rothblatt, Ph.D., United Therapeutics, ... launch this quarter of our extended-release tablet ...
(Date:7/29/2014)... Dr. Jason Wendel – recipient of a Regional Top Doctor ... 10 Plastic Surgeon Specialists for Nashville, TN – has released ... includes a Hydration Booster, Retexturing Night Crème, and Anti-aging C ... younger, more radiant appearance while protecting them from the sun’s ... why at Dr. J. J. Wendel Plastic Surgery, we have ...
Breaking Biology Technology:Global Surgical Equipment Market is expected to reach $12.1 billion by 2020 - Allied Market Research 2Global Surgical Equipment Market is expected to reach $12.1 billion by 2020 - Allied Market Research 3Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 2Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 11United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 12United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 13Dr. J. J. Wendel Launches New Line of Skin Care Products 2
... July 9 Abt Bio-Pharma Solutions, Inc.,(ABS), ... economic, and,strategic commercialization solutions, is pleased to ... and business strategy, has been promoted to,Executive ... succeeding Susan Windham-Bannister, who has been appointed,President ...
... Provides expertise in high-growth therapeutic areas to pharmaceutical and ... biotechnology companies ... the last year, BEVERLY HILLS, Calif., July 9 Worldwide Clinical,Trials, ... reached a milestone in establishing itself as a premier global,contract research organization ...
... July 9 Cepheid (Nasdaq:,CPHD) today announced ... on Healthcare Associated Infections, Fred Tenover, Ph.D., ... will serve as a liaison,with the Infection ... Infection (HAI) Consortium program., "The objective ...
Cached Biology Technology:Abt Bio-Pharma Solutions, Inc. Names Nandini Hadker as Executive Director, Succeeding Susan Windham-Bannister 2Abt Bio-Pharma Solutions, Inc. Names Nandini Hadker as Executive Director, Succeeding Susan Windham-Bannister 3Worldwide Clinical Trials Emerges as Leading Global Contract Research Organization 2Worldwide Clinical Trials Emerges as Leading Global Contract Research Organization 3Noted Molecular Epidemiologist Joins Cepheid to Head Healthcare Associated Infection Consortium Program 2Noted Molecular Epidemiologist Joins Cepheid to Head Healthcare Associated Infection Consortium Program 3
(Date:7/29/2014)... from scientists at the University of Kent has shown ... are regulated a breakthrough that could have a ... from Kent,s School of Biosciences uncovered the mechanism whereby ... known as actin filaments are ,fine-tuned, to ... filaments appear to completely stable, providing a framework for ...
(Date:7/29/2014)... new book that brings together two of the major ... profile of insect fossils through stunning photographs and unique ... James E Jepson, details the incredible preservation and diversity ... scene for what these remarkable fossils can tell us ... future of our planet. Like the mosquito in Jurassic ...
(Date:7/28/2014)... Food and Drug Administration (FDA) for other purposes can ... human cells, including those that cause Legionnaires, disease, brucellosis, ... mBio , the online open-access journal of the American ... non-antibiotic drugs that could one day help curb bacterial ... list inhibit the growth of at least three of ...
Breaking Biology News(10 mins):Unique images bring fossil insects back to life 2New route to identify drugs that can fight bacterial infections 2
... 20, 2013  Medbox, Inc. (OTC Markets: MDBX) ( www.medboxinc.com ), ... implementing the Colorado marijuana task force,s ... force recommended marijuana be made available to tourists over the ... available to in-state residents. Representative Dan Pabon ...
... and red wine, may have the potential to protect against ... from Henry Ford Hospital in Detroit. The study shows ... effects of noise-induced hearing loss when given resveratrol before being ... "Our latest study focuses on resveratrol and its effect ...
... February 20, 2013 Ron Davis, PhD, chair of ... Scripps Research Institute, has been selected to receive a ... for his work on the complex biology of memory ... The National Institute of Neurological Disorders and Stroke (NINDS), ...
Cached Biology News:Colorado Marijuana Task Force Gives Green Light To "Pot Tourism" 2Study: Resveratrol shows promise to protect hearing, cognition 2Scripps Florida scientist awarded prestigious Javits Neuroscience Investigator Award 2
... Blot includes 7 lanes ... from Alzheimer's-diseased brain tissue ... gyrus, frontal lobe, temporal ... lobe and cerebellum. Patent/trademark/license ...
... Rabbit, and media. Cryo-preserved cells in medium ... passage 25 (approx), supplied with kit (500 ... supplied as a long-term culture, and is ... of continuous growth from the date supplied, ...
... use spatulas have been designed to save ... for those interested in eliminating the recycling ... spatula is individually packaged, RNase/DNase free, non-pyrogenic ... a new product number, created to easily ...
... protein microarray is the first microarray product ... on a proteome scale. The Yeast ProtoArray ... (ORFs) expressed as 5'-GST fusions, purified and ... x 3 inch nitrocellulose-coated slide. With the ...
Biology Products: